


WHAT IS CLAIMED IS:

1. A crystalline form of Compound I:



which is Compound I Form C, characterized by an X-ray powder diffractogram comprising peaks ($\pm 0.2^\circ$) at 7.3 , 23.3 and $28.2^\circ 2\theta$ as determined on a diffractometer using Cu-K α radiation.

2. Compound I Form C according to claim 1, further comprising:

peaks at 16.6 and $20.9^\circ 2\theta \pm 0.2^\circ$.

3. Compound I according to claim 1, further comprising a differential scanning calorimetry (DSC) thermogram comprising an endotherm at about 234°C .

4. A process of preparing a capsule comprising Compound I Form C according to any one of claims 1 to 3 comprising combining Compound I Form C with a pharmaceutically acceptable carrier or excipient.

5. A process of preparing a tablet comprising Compound I Form C according to any one of claims 1 to 3 comprising combining Compound I Form C with a pharmaceutically acceptable carrier or excipient.

6. Use of Compound I Form C according to any one of claims 1 to 3 in the preparation of a medicament for treating a subject suffering from or at risk of a disease or condition mediated by a protein kinase selected from c-fms, c-kit, Flt3 or combinations thereof,

wherein the disease or condition is selected from breast cancer, unresectable or metastatic melanoma with a KIT mutation, glioblastoma, acute myeloid leukemia, alopecia, baldness, wound healing, androgenetic alopecia (AGA), epilepsy, traumatic brain injury, tauopathies, Erdheim Chester Disease, Langerhans cell histiocytosis, hairy cell leukemia, non-small cell lung

cancer, scleroderma, anterior eye disease, posterior eye disease, lysosomal storage disease, stem cell ablation and myelopreparation for stem cell transplant, primary progressive multiple sclerosis, complex regional pain syndrome, reflex sympathetic dystrophy, muscular dystrophy, duchenne muscular dystrophy, causalgia, neuro-inflammation, neuroinflammatory disorders, benign forgetfulness, HIV, binswager type dementia, dementia with lewy bodie, prosencephaly, microencepahy, cerebral palsy, congenital hydrocephalus, abdominal dropsy, progressive supranuclear palsy, glaucoma, addiction disorders, dependencies, alcoholism, tremors, Wilson's disease, vascular dementias, multi infarct dementia, fronto temporal dementia, pseudo-dementia, bladder cancer, ureter cancer, urethra cancer, urachus cancer, basal cell carcinoma, cholangiocarcinoma, colon cancer, endometrial cancer, esophageal cancer, Ewing's sarcoma, gastric cancer, glioma, hepatocellular carcinoma, Hodgkin lymphoma, laryngeal carcinoma, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, pancreatic cancer, rectal cancer, renal cancer, squamous cell carcinoma, t cell lymphoma, thyroid cancer, monocytic leukemia, pheochromocytoma, malignant peripheral nerve cell tumors, malignant peripheral nerve sheath tumors (MPNST), cutaneous and plexiform neurofibromas, leiomyoadenomatoid tumor, fibroids, uterine fibroids, leiomyosarcoma, papillary thyroid cancer, anaplastic thyroid cancer, medullary thyroid cancer, follicular thyroid cancer, hurthle cell carcinoma, thyroid cancer, angiosarcomas, liposarcomas, ascites, malignant ascites, mesothelioma, salivary gland tumors, mucoepidermoid carcinoma of the salivary gland, acinic cell carcinoma of the salivary gland, gastrointestinal stromal tumors (GIST), tumors that cause effusions in potential spaces of the body, pleural effusions, pericardial effusions, peritoneal effusions aka ascites, giant cell tumors (GCT), GCT of bone, pigmented villonodular synovitis (PVNS), tenosynovial giant cell tumor (TGCT), TCGT of tendon sheath (TGCT-TS), ovarian cancer, Alzheimer's disease, colorectal carcinoma, neurofibromatosis, bone osteolysis, bone pain, prostate cancer, tumor angiogenesis, paracrine tumor growth or tumors that express aberrantly or otherwise Fms, CSF1R, CSF1 or IL-34, or activating mutations or translocations of any of the foregoing.

7. Use of Compound I Form C according to any one of claims 1 to 3 and a pharmaceutically acceptable excipient in the preparation of a medicament for treating a subject suffering from or at risk of a disease or condition mediated by a protein kinase selected from c-fms, c-kit, Flt3 or combinations thereof, wherein the disease or condition is selected from breast

cancer, unresectable or metastatic melanoma with a KIT mutation, glioblastoma, acute myeloid leukemia, alopecia, baldness, wound healing, androgenetic alopecia (AGA), epilepsy, traumatic brain injury, tauopathies, Erdheim Chester Disease, Langerhans cell histiocytosis, hairy cell leukemia, non-small cell lung cancer, scleroderma, anterior eye disease, posterior eye disease, lysosomal storage disease, stem cell ablation and myeloablation for stem cell transplant, primary progressive multiple sclerosis, complex regional pain syndrome, reflex sympathetic dystrophy, muscular dystrophy, duchenne muscular dystrophy, causalgia, neuroinflammation, neuroinflammatory disorders, benign forgetfulness, HIV, binswanger type dementia, dementia with lewy bodies, prosencephaly, microencephaly, cerebral palsy, congenital hydrocephalus, abdominal dropsy, progressive supranuclear palsy, glaucoma, addiction disorders, dependencies, alcoholism, tremors, Wilson's disease, vascular dementias, multi infarct dementia, fronto temporal dementia, pseudo-dementia, bladder cancer, ureter cancer, urethra cancer, urachus cancer, basal cell carcinoma, cholangiocarcinoma, colon cancer, endometrial cancer, esophageal cancer, Ewing's sarcoma, gastric cancer, glioma, hepatocellular carcinoma, Hodgkin lymphoma, laryngeal carcinoma, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, pancreatic cancer, rectal cancer, renal cancer, squamous cell carcinoma, t cell lymphoma, thyroid cancer, monocytic leukemia, pheochromocytoma, malignant peripheral nerve cell tumors, malignant peripheral nerve sheath tumors (MPNST), cutaneous and plexiform neurofibromas, leiomyosarcoma, leiomyosarcoma, leiomyosarcoma, papillary thyroid cancer, anaplastic thyroid cancer, medullary thyroid cancer, follicular thyroid cancer, hurthle cell carcinoma, thyroid cancer, angiosarcomas, liposarcomas, ascites, malignant ascites, mesothelioma, salivary gland tumors, mucoepidermoid carcinoma of the salivary gland, acinic cell carcinoma of the salivary gland, gastrointestinal stromal tumors (GIST), tumors that cause effusions in potential spaces of the body, pleural effusions, pericardial effusions, peritoneal effusions aka ascites, giant cell tumors (GCT), GCT of bone, pigmented villonodular synovitis (PVNS), tenosynovial giant cell tumor (TGCT), TCGT of tendon sheath (TGCT-TS), ovarian cancer, Alzheimer's disease, colorectal carcinoma, neurofibromatosis, bone osteolysis, bone pain, prostate cancer, tumor angiogenesis, paracrine tumor growth or tumors that express aberrantly or otherwise Fms, CSF1R, CSF1 or IL-34, or activating mutations or translocations of any of the foregoing.

8. The use according to claim 6 or 7 wherein the medicament comprises another therapeutic agent, wherein the other therapeutic agent is: i) an alkylating agent; ii) an antibiotic; iii) an antimetabolite; iv) an antibody therapy agent; v) a hormone or hormone antagonist; vi) a taxane; vii) a retinoid; viii) an alkaloid; ix) an antiangiogenic agent; x) a topoisomerase inhibitor; xi) a kinase inhibitor selected from a PI3K inhibitor, Cdk4 inhibitors; an Akt inhibitor; a Mek inhibitor, or an EGFR inhibitor; xii) a targeted signal transduction inhibitor; xiii) a biological response modifier; xiv) a chemotherapeutic agent; xv) an Hsp90 inhibitor; xvi) a farnesyltransferase inhibitor; xvii) an aromatase inhibitor; xviii) an IDO inhibitor; xix) a histone acetyltransferase (HAT) inhibitor; xx) histone deacetylase (HDAC) inhibitor; xxi) a sirtuin (SIRT) inhibitor; xxii) a BET inhibitor; or xxiii) an antiangiogenic agent.
9. Use of Compound I Form C according to any one of claims 6 to 8 in the preparation of a medicament for treating a subject suffering from or at risk of tenosynovial giant cell tumor (TGCT).
10. Use of Compound I Form C according to any one of claims 6 to 8 in the preparation of a medicament for treating a subject suffering from or at risk of pigmented villonodular synovitis (PVNS).
11. Use of Compound I Form C according to any one of claims 6 to 8 in the preparation of a medicament for treating a subject suffering from or at risk of malignant peripheral nerve sheath tumors (MPNST).
12. The use according to any one of claims 9 to 11, wherein the medicament further comprises sirolimus.
13. Use of Compound I Form C according to any one of claims 6 to 8 in the preparation of a medicament for treating a subject suffering from or at risk of plexiform neurofibromas.
14. Use of Compound I Form C according to any one of claims 6 to 8 in the preparation of a medicament for treating a subject suffering from or at risk of ovarian cancer.

15. The use according to claim 14, further comprising administering to the subject a therapeutically effective amount of paclitaxel.
16. Use of Compound I Form C according to any one of claims 6 to 8 in the preparation of a medicament for treating a subject suffering from or at risk of Alzheimer's disease.
17. The use according to any one of claims 6 to 8, wherein the disease or condition is pancreatic cancer.
18. The use according to any one of claims 6 to 8 wherein the disease or condition is colorectal carcinoma.
19. The use according to claim 17 or 18, wherein the medicament further comprises durvalumab.
20. The use according to any one of claims 6 to 8 wherein the disease or condition is neurofibromatosis.
21. The use according to any one of claims 6 to 8 wherein the disease or condition is bone osteolysis and/or bone pain.
22. The use according to any one of claims 6 to 8 wherein the disease or condition is prostate cancer.